QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 限定条件 发表日期：2017    专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Dihydroartemisinin selectively inhibits PDGFR alpha-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR alpha protein 期刊论文 CELL DISCOVERY, 2017, 卷号: 3 作者:  Li, Xiaoguang;  Ba, Qian;  Liu, Yanling;  Yue, Qingxi;  Chen, Peizhan 收藏  |  浏览/下载：43/0  |  提交时间：2019/01/08 Dihydroartemisinin  Epithelial-mesenchymal transition  metastasis  ovarian cancer  PDGFR alpha   Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy 期刊论文 ACTA PHARMACOLOGICA SINICA, 2017, 卷号: 38, 期号: 11, 页码: 1521-1532 作者:  Chen, Wen-hua;  Song, Shan-shan;  Qi, Ming-hui;  Huan, Xia-juan;  Wang, Ying-qing 收藏  |  浏览/下载：26/0  |  提交时间：2019/01/08 PARP-1 inhibitor  olaparib  breast cancer  BRCA-deficient tumors   Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 138, 页码: 514-531 作者:  Chen, Wenhua;  Guo, Ne;  Qi, Minghui;  Dai, Haiying;  Hong, Minghuang 收藏  |  浏览/下载：30/0  |  提交时间：2019/01/08 Antitumor drug  BRCA1/2  PARP inhibitors  Molecular docking   Programmed Multiresponsive Vesicles for Enhanced Tumor Penetration and Combination Therapy of Triple-Negative Breast Cancer 期刊论文 ADVANCED FUNCTIONAL MATERIALS, 2017, 卷号: 27, 期号: 20 作者:  Zhou, Fangyuan;  Feng, Bing;  Wang, Tingting;  Wang, Dangge;  Meng, Qingshuo 收藏  |  浏览/下载：32/0  |  提交时间：2019/01/08 TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 16, 页码: 26718-26731 作者:  Tao, Yi;  Yang, Guang;  Yang, Hongxing;  Song, Dongliang;  Hu, Liangning 收藏  |  浏览/下载：59/0  |  提交时间：2019/01/08 TRIP13  multiple myeloma  prognosis  drug resistance  MAD2   Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials 期刊论文 CANCER LETTERS, 2017, 卷号: 386, 页码: 47-56 作者:  Yuan, Bo;  Ye, Na;  Song, Shan-Shan;  Wang, Yu-Ting;  Song, Zilan 收藏  |  浏览/下载：43/0  |  提交时间：2019/01/08 Homologous recombination repair defects  Olaparib  Growth inhibition  Patient-derived xenografts  Pharmacokinetics   discoveryofpotent24difluorolinkerpolyadpribosepolymerase1inhibitorswithenhancedwatersolubilityandinvivoanticancerefficacy 期刊论文 actapharmacologicasinica, 2017, 卷号: 38, 期号: 11, 页码: 1521 作者:  Chen Wenhua;  Song Shanshan;  Ql Minghui;  Huan Xiajuan;  Wang Yingqing 收藏  |  浏览/下载：5/0  |  提交时间：2020/07/01 PARP INHIBITORS  MEDICINAL CHEMISTRY  DRUG DISCOVERY  CANCER  THERAPY  DESIGN  FLUORINE  SUCCESS  PREDICT  METRICS  PARP-1 inhibitor  olaparib  breast cancer  BRCA-deficient tumors